Research Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, 113-8421, Japan.
Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.
Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody structure, stability, and efficacy. Here, we established a cell-based immunotoxin screening system to facilitate the isolation of functional antibodies with internalization capacities, and discovered an anti-human CD71 monoclonal antibody. To overcome the limitation of drug-to-antibody ratio, we employed the encapsulation capacity of liposome, and developed anti-CD71 antibody-conjugated liposome that demonstrated antigen-antibody dependent cellular uptake when its synthesis was optimized. Furthermore, anti-CD71 antibody-conjugated liposome encapsulating doxorubicin demonstrated antigen-antibody dependent cytotoxicity. In summary, this study demonstrates the powerful pipeline to discover novel functional antibodies, and the optimal method to synthesize immunoliposomes. This versatile technology offers a rapid and direct approach to generate antibodies suitable for drug delivery modalities.
单克隆抗体的开发对于靶向药物输送至关重要,因为其特性决定了改善治疗效果和降低副作用。抗体疗法针对表面分子;因此,需要内化来进行药物输送。作为抗体药物偶联物,一个关键参数是药物与抗体的比率,其中连接到抗体上的药物数量会影响抗体的结构、稳定性和功效。在这里,我们建立了一种基于细胞的免疫毒素筛选系统,以促进具有内化能力的功能性抗体的分离,并发现了一种抗人 CD71 单克隆抗体。为了克服药物与抗体比率的限制,我们利用了脂质体的包封能力,并开发了抗 CD71 抗体偶联脂质体,当优化其合成时,表现出抗原-抗体依赖的细胞摄取。此外,当优化其合成时,包载阿霉素的抗 CD71 抗体偶联脂质体表现出抗原-抗体依赖的细胞毒性。总之,本研究展示了发现新型功能抗体的强大途径,以及合成免疫脂质体的最佳方法。这项多功能技术提供了一种快速而直接的方法来产生适合药物输送方式的抗体。